Werewolf Therapeutics Announced Initial Results From Phase 1 Trial Of WTX-330 As Monotherapy For Immunotherapy Insensitive Or Resistant Locally Advanced Or Metastatic Solid Tumors Or Non-Hodgkin Lymphoma, Additional Results Expected In Q4 Of 2024

6/25/24 7:11:59 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $HOWL alert in real time by email

Get the next $HOWL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HOWL

Date	Price Target	Rating	Analyst
4/3/2024	$12.00	Mkt Outperform	JMP Securities
8/24/2023	$9.00	Outperform	Wedbush
6/6/2023	$11.00 → $12.00	Buy	Jefferies
11/19/2021	$29.00 → $28.00	Outperform	SVB Leerink
9/10/2021	$26.00	Buy	BofA Securities

More analyst ratings

$HOWL
Press Releases

Fastest customizable press release news feed in the world

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals - - Additional preclinical data demonstrate INDUKINETM molecules' anti-tumor potency with distinct immune activation profiles across four cytokines - WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune mediated conditions, today shared
11/7/24 9:02:00 AM ET
$HOWL
Biotechnology: Pharmaceutical Preparations
Health Care
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
– Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting – – Monotherapy and combination expansion arms open and enrolling in ongoing Phase 1/1b clinical trial of WTX-124; initial efficacy data from monotherapy expansion arms anticipated in the first half of 2025 – – Introduced WTX-921, a promising new development candidate and first-of-its kind IL-10 INDUKINE™ molecule for the treatment of inflammatory diseases – – Updated cash guidance provides runway through at least the second quarter of 2026 – WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeu
11/7/24 9:00:00 AM ET
$HOWL
Biotechnology: Pharmaceutical Preparations
Health Care
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced the addition of WTX-921, a novel IL-10 INDUKINE development candidate for Inflammatory Bowel Disease (IBD) and potentially other inflammatory diseases, to the Company's pipeline. This pipeline expansion underscores the transformative promise of the Werewolf's PREDATOR® platform to apply the INDUKINE approach to therapeutic areas outs
10/31/24 8:00:00 AM ET
$HOWL
Biotechnology: Pharmaceutical Preparations
Health Care

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors. "Mike is a world-renowned oncologist and clinical researcher who has made countless contributions to the field of cancer immunotherapy. I am delighted to have Mike join our Board at this important time in the clinical development of our WTX-124 and WTX-330 INDUKINE molecules," sai
1/4/24 4:05:00 PM ET
$HOWL
Biotechnology: Pharmaceutical Preparations
Health Care
Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Meeta Chatterjee, Ph.D., Senior Vice President of Global Business Development at Legend Biotech Corporation, as a member of its board of directors. "I am thrilled to join Werewolf's board of directors as the company prepares to advance investigational new drug applications for its two lead INDUKINETM product candidates, WTX-124 and WTX-330, for the treatment of solid tumors," sai
10/28/21 4:01:00 PM ET
$HOWL
Biotechnology: Pharmaceutical Preparations
Health Care
Werewolf Therapeutics Appoints Chulani Karunatilake, Ph.D. as Chief Technology Officer
Veteran life sciences executive brings more than 30 years CMC and product development strategy expertise to rapidly advance programs and oversee manufacturing CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Chulani Karunatilake, Ph.D. as Chief Technology Officer (CTO). Dr. Karunatilake brings more than 30 years of experience in Chemistry and Manufacturing Controls (CMC) process and strategy development and will oversee manufac
6/15/21 7:00:00 AM ET
$HOWL
Biotechnology: Pharmaceutical Preparations
Health Care

Werewolf Therapeutics Announced Initial Results From Phase 1 Trial Of WTX-330 As Monotherapy For Immunotherapy Insensitive Or Resistant Locally Advanced Or Metastatic Solid Tumors Or Non-Hodgkin Lymphoma, Additional Results Expected In Q4 Of 2024

Chat with this insight

Recent Analyst Ratings for $HOWL

$HOWL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Ra Capital Management, L.P.

SEC Form 4 filed by Dirocco Derek

SEC Form 4 filed by Morrison Briggs

$HOWL Press Releases

Fastest customizable press release news feed in the world

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

$HOWL Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Werewolf Therapeutics Inc. (Amendment)

SEC Form SC 13D/A filed by Werewolf Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Werewolf Therapeutics Inc. (Amendment)

$HOWL Financials

Live finance-specific insights

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

$HOWL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

JMP Securities initiated coverage on Werewolf Therapeutics with a new price target

Wedbush initiated coverage on Werewolf Therapeutics with a new price target

Jefferies resumed coverage on Werewolf Therapeutics with a new price target

$HOWL Market Insights

Live Market Insights

$HOWL Leadership Updates

Live Leadership Updates

$HOWL SEC Filings

HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target

JMP Securities Reiterates Market Outperform on Werewolf Therapeutics, Maintains $12 Price Target

Where Werewolf Therapeutics Stands With Analysts

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors

Werewolf Therapeutics Appoints Chulani Karunatilake, Ph.D. as Chief Technology Officer

SEC Form 10-Q filed by Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

SEC Form S-8 POS filed by Werewolf Therapeutics Inc.

Recent Analyst Ratings for
$HOWL

$HOWL
Insider Trading

$HOWL
Press Releases

$HOWL
Large Ownership Changes

$HOWL
Financials

$HOWL
Analyst Ratings

$HOWL
Market Insights

$HOWL
Leadership Updates

$HOWL
SEC Filings